ARWR · Arrowhead Pharmaceuticals, Inc.
Market Cap
$11.64B
Shares
141.25M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$84.91
Open$87.99
Day$84.20–88.25
52W close$22.03–89.59
Avg vol 30d1.6M
Short int9.2M · 6.5% float · 7.8d
Short vol61%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 9 wks
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+21%
above
Price vs 50-day avg
+2%
above
RSI (14)
47
neutral
MACD trend
Negative
52-week position
93%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
+40%
trailing
YTD return
+28%
this year
Relative strength
+27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $84 › 200d $70 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +125 funds added
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Falling
6.52% of float · ▼ -4.6% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
507 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
−49%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$156.9M
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2023
next several quarters
Operating burn
$80M – $100M
this year
R&D expenditures
$80M
beginning the second fiscal quarter
Normalized spend / quarterly burn
$80M – $100M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2023
Operating cash burn
· fiscal 2024
$110M – $130M
Full year capital expenditures
· fiscal 2024
$150M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+21%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
93%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $84 › 200d $70 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +125 funds added
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Falling
6.52% of float · ▼ -4.6% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
507 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22
Now $85 · 93%
Range high $90
vs 200-day avg +21%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Acute pancreatitis event reduction versus placebo across sHTG study population | 78% | fiscal 2026 third quarter | — |
| ARO-PNPLA3 dose-dependent mean reduction in liver fat | 40% | fiscal 2026 third quarter | — |
| Madrigal development, regulatory, and sales milestone payments | $975M | fiscal 2026 third quarter | — |
| SHASTA-3 median triglyceride reduction from baseline | 79% | fiscal 2026 third quarter | — |
| SHASTA-4 median triglyceride reduction from baseline | 81% | fiscal 2026 third quarter | — |
| Unique practitioners that have prescribed REDEMPLO | 400 | fiscal 2026 third quarter | — |
| YOSEMITE target enrollment | 70 | fiscal 2026 third quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARWR
this stock
Arrowhead Pharmaceuticals, Inc.
|
$11.64B | +27.9% | -48.6% | — | 6.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARWR | -2.5% | +0.3% | +40.0% | +0.3% | +27.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -3.0% | -2.7% | +26.5% | -2.7% | +15.1% |
Key facts
CIK
879407
CUSIP
04280A100
13F (30d)
381 filings
373 filers
Visit website
Investor relations